Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Cell-surface receptors are the targets for more than 60% of current drugs. Traditionally, optimizing the interaction of lead molecules with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action. However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site, known as allosteric sites. Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.

Original languageEnglish
Pages (from-to)198-210
Number of pages13
JournalNature Reviews Drug Discovery
Volume1
Issue number3
Publication statusPublished - 1 Mar 2002
Externally publishedYes

Cite this

@article{d0eea2f1871f484e81702b58bd426bf3,
title = "Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery",
abstract = "Cell-surface receptors are the targets for more than 60{\%} of current drugs. Traditionally, optimizing the interaction of lead molecules with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action. However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site, known as allosteric sites. Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.",
author = "Arthur Christopoulos",
year = "2002",
month = "3",
day = "1",
language = "English",
volume = "1",
pages = "198--210",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "3",

}

Allosteric binding sites on cell-surface receptors : Novel targets for drug discovery. / Christopoulos, Arthur.

In: Nature Reviews Drug Discovery, Vol. 1, No. 3, 01.03.2002, p. 198-210.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Allosteric binding sites on cell-surface receptors

T2 - Novel targets for drug discovery

AU - Christopoulos, Arthur

PY - 2002/3/1

Y1 - 2002/3/1

N2 - Cell-surface receptors are the targets for more than 60% of current drugs. Traditionally, optimizing the interaction of lead molecules with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action. However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site, known as allosteric sites. Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.

AB - Cell-surface receptors are the targets for more than 60% of current drugs. Traditionally, optimizing the interaction of lead molecules with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action. However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site, known as allosteric sites. Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.

UR - http://www.scopus.com/inward/record.url?scp=0036490942&partnerID=8YFLogxK

M3 - Review Article

VL - 1

SP - 198

EP - 210

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 3

ER -